SCHEMBL1338764

SCHEMBL1338764

Cn1c(=O)c(-c2ccc(Cl)cc2Cl)cc2c3cc(-c4ncco4)ccc3n(C)c21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BRD4 O60885 2/20 0.41
▸ KDM4E B2RXH2 2/20 0.40
▸ ALDH1A1 P00352 2/20 0.40
▸ GAA P10253 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ F2RL3 Q96RI0 1/20 0.36
▸ TNKS O95271 1/20 0.36
▸ CNR1 P21554 7/20 0.36
▸ CNR2 P34972 7/20 0.36
▸ CCNC P24863 1/20 0.35
▸ CDK8 P49336 1/20 0.35
▸ HSD11B1 P28845 2/20 0.35
▸ MAPT P10636 1/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35
▸ RXFP1 Q9HBX9 1/20 0.35
▸ GABRA1 P14867 4/20 0.34
▸ GABRG2 P18507 3/20 0.34
▸ GABRB3 P28472 3/20 0.34
▸ GABRA5 P31644 3/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1338640 0.83 KDM4E (0.41) KDM4EALDH1A1GAAHPGDHSD17B10
SCHEMBL1339468 0.83 KDM4E (0.41) KDM4EALDH1A1GAAHPGDHSD17B10
SCHEMBL3574329 0.82 HSD17B10 (0.42) KDM4EALDH1A1GAAHPGDHSD17B10
SCHEMBL1340416 0.82 ALDH1A1 (0.39) KDM4EALDH1A1GAAHPGDHSD17B10
SCHEMBL3577543 0.82 KDM4E (0.41) BRD4KDM4EALDH1A1GAAHPGD
SCHEMBL1339131 0.81 NOTUM (0.39) KDM4EALDH1A1GAAHPGDHSD17B10
SCHEMBL1380418 0.81 KDM4E (0.41) KDM4EALDH1A1GAAHPGDHSD17B10
SCHEMBL1338617 0.80 KDR (0.39) KDM4EALDH1A1GAAHPGDHSD17B10
SCHEMBL1339274 0.80 KDM4E (0.40) KDM4EALDH1A1GAAHPGDHSD17B10
SCHEMBL1338643 0.80 KDM4E (0.38) KDM4EALDH1A1GAAHPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063061-B2 6-(2-amino-1,3-thiazol-4-yl)-3-(2,4-dichlorophenyl)-1-methyl-1,9-dihydro-2H-pyrido[2,3-b]indol-2-one; affinity for GABAA-receptor-associated omega modulatory sites SANOFI-AVENTIS (FR) 2011-11-22 — — US disclosed
EP-1940840-B1 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2010-07-21 — — EP disclosed
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof SANOFI-AVENTIS (FR) 2008-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof CYP11B2, CYP11B1, CYP2D6 BRD4 1004/4885KDM4E 1908/4885ALDH1A1 283/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback